MLL methylation is not likely a common mechanism for therapy-related AML Leukemia (2005) Some observations support the hypothesis that hypomethylation is associated with increased DNA recombination, chromosomal aberrations, mitotic dysfunction and translocations, 1, 2 and an increased tumor formation rate. 3, 4 The MLL gene is often disrupted by chromosomal translocation in infant ALL and AML, in de novo AML, and in therapy-related myeloid leukemia (t-ML) following topoisomerase II inhibitors, such as etoposide. MLL seems to be particularly prone to cleavage following exposure to apoptotic stimuli, and it has been suggested that MLL transcription is required for its rearrangement. We investigated whether there was interindividual variability in methylation status of the MLL gene itself, as such epigenetic variability could predispose to leukemia or t-ML. We used DNA from blasts from nine patients (five diagnostic ALL and four t-ML, all carrying an MLL rearrangement), and from two leukemia cell lines (CEM and Nalm-6). As controls, we also screened DNA from lymphoblastoid cell lines from the DNA Polymorphism Discovery Resource subset (n ¼ 8, Coriell Institute), which are representative of human genetic variability. 5 Using Methprimer (http://www.ucsf.edu/urogene/methprimer), we established the location of five hypothetical CpG islands in MLL (Figure 1) , two of which were in the MLL breakpoint cluster region (BCR). We used bisulfite PCR to amplify each CpG island (PCR products from 500 to 1000 bp) to asses the methylation status of each. 6 To decrease PCR product size, the promoter CpG island was amplified in two separate reactions.
We found the same methylation pattern in all the samples tested: the extended CpG island in the promoter region upstream of the ATG start site was not methylated, whereas all the CpG islands located in the open reading frame of MLL were methylated. We also assessed methylation status of the CEM and Nalm6 cell lines 24 h after treatment with 10 mM 6-mercaptopurine for 8 and 24 h, and 24 h after 10 mM etoposide for 4, 8 and 24 h. We found no change in methylation status of the CpG islands as a result of anticancer drug treatment.
Although the unmethylated status of the MLL promoter is consistent with active transcription being required for its rearrangements, the lack of variability among samples, and the fact that it was unmethylated in normal cells and in cells bearing MLL translocations, suggests that promoter methylation variability is unlikely to identify individuals at risk for MLL The Philadelphia chromosome (Ph) derives from a balanced translocation between chromosomes 9 and 22, and results in a BCR-ABL fusion gene. In the vast majority of Ph þ leukemias, breakpoints in the ABL gene are distributed over a B200 kb breakpoint region between exons 1b and a2, while breakpoints in the BCR gene are clustered in three well-defined regions.
1 Figure 1 Schematic representation of the CpG island locations along the MLL gene. The black box represents the location of the breakpoint cluster region (BCR), the hypothetical CpG islands according to Methprimer are defined by numbers that represent the chromosomal position of starting and ending base pair of each island according to UCSC Genome Browser (http://genome.ucsc.edu, hg17).
